Perspective Therapeutics, Inc. CATX 深 沪
等待开盘 01-29 09:30:00 美东时间
2.56
-0.140
-5.19%
华盛通- 最 高2.70
- 今 开2.70
- 成交量 49.85万股
- 最 低 2.55
- 昨 收 2.70
- 总市值 1.90亿
- 52周最高 5.3881
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 1.60
- 委 比 -19.76%
- 总股本 7426.30万
- 历史最高 37.90
- 量 比 0.62
- 振 幅 5.56%
- 历史最低 1.60
- 每 手 1
- 风险率 0.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
01-13 20:24
Perspective Therapeutics shares are trading lower. The company issued business updates and strategic priorities for the next 12-18 months.
Perspective Therapeutics shares are trading lower. The company issued business ...
01-13 01:07
Perspective Therapeutics to Showcase New Cancer Treatment Data at Major Medical Conference
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated
2025-12-04 20:05
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
B. Riley Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $11
B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $12 to $11.
2025-11-19 00:57
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) shares rose 119.1% to $9.86 during Monda...
2025-10-21 02:39
